20501 ⎘
Medicinal preparations containing organic active ingredients; Phosphorus compounds Amides of phosphorus acids
Anti-CD38 Antibodies for Treatment of Light Chain Amyloidosis and Other CD38-Positive Hematological Malignancies
#2USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)
#3METHODS OF CONDITIONING PATIENTS FOR T CELL THERAPY
#4METHODS AND COMPOSITIONS FOR INFUSION OF TRANSIENTLY ENGRAFTING, SELECTED POPULATIONS OF ALLOGENEIC LYMPHOCYTES TO TREAT CANCER
#5TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS
#6ANTICANCER DRUGS AND METHODS OF MAKING AND USING SAME
#7METHODS AND COMPOSITIONS FOR NON-MYELOABLATIVE BONE MARROW RECONSTITUTION
#8METHODS FOR THE TREATMENT OF B CELL MALIGNANCIES USING ADOPTIVE CELL THERAPY
#9METHODS AND COMPOSITIONS FOR DOSING OF ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR T CELLS
#10PRIMING OF CANCER CELLS WITH LOW DOSE NALTREXONE
#11IL-8 INIHIBITORS FOR USE IN THE TREATMENT OF SOME UROLOGICAL DISORDERS
#12Anti-CD38 Antibodies for Treatment of Light Chain Amyloidosis and Other CD38-Positive Hematological Malignancies
#13COMPOSITIONS AND METHODS FOR FORECASTING RESPONSE TO LUPUS NEPHRITIS (LN)THERAPY
#14METHODS FOR PREVENTING AND TREATING ACUTE KIDNEY INJURY
#15MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING BONE RELATED DISEASES AND SYMPTOMS
#16COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER USING BACTERIA
#17IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF
#18METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
#19TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES
#20COMPOSITIONS AND METHODS OF CELLULAR IMMUNOTHERAPY
#21COMPOSITIONS AND METHODS FOR SELECTIVE ELIMINATION AND REPLACEMENT OF HEMATOPOIETIC STEM CELLS
#22TREATMENT OF CANCER WITH NK CELLS AND A HER2 TARGETED ANTIBODY
#23COMPOSITIONS AND METHODS FOR SELECTIVE ELIMINATION AND REPLACEMENT OF HEMATOPOIETIC STEM CELLS
#24DPEP-1 Binding Compositions and Methods of Use
#25CD40L ANTAGONIST AND USES THEREOF IN THE TREATMENT OF LUPUS NEPHRITIS
#26Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells
#27USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME AND CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISONE
#28ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF
#29COMBINATION TREATMENT OF AN ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY AND CHEMOTHERAPY
#30ANTI-VIRAL CENTRAL MEMORY CD8+ VETO CELLS IN HAPLOIDENTICAL STEM CELL TRANSPLANTATION
#31TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES
#32MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING BONE RELATED DISEASES AND SYMPTOMS
#33METHODS FOR ASSESSING THE SEVERITY AND PROGRESSION OF SARS-COV2 INFECTIONS USING CELL-FREE DNA
#34METHOD AND COMPOSITION FOR INHIBITING VIRUS INFECTION
#35METHOD FOR TREATING A GD2-POSITIVE CANCER
#36SELECTION OF IMPROVED TUMOR REACTIVE T-CELLS
#37USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)
#38OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT
#39USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)
#40METHODS OF TREATING A CORONAVIRUS INFECTION
#41CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING CEA AND ANTI-CEA-IL2 IMMUNOCYTOKINES FOR CANCER THERAPY
#42METHODS OF CONDITIONING PATIENTS FOR T CELL THERAPY
#434-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE
#44Treatment of aneurysms
#45CANCER IMMUNOTHERAPY USING TRANSFUSIONS OF ALLOGENEIC, TUMOR-SPECIFIC CD4+ T CELLS
#46METHODS OF TREATING TUMORS
#47FORMULATIONS OF CREATINE AND CYCLODEXTRIN EXHIBITING IMPROVED BIOAVAILABILITY
#48COMPOSITIONS AND METHODS FOR INHIBITING TUMOR-INDUCED IMMUNE SUPPRESSION
#49METHODS FOR CANCER IMMUNOTHERAPY
#50METHODS OF TREATMENT USING G-CSF PROTEIN COMPLEX
#51NOVEL COMPOUNDS AND FORMULATIONS
#52COMBINATION OF A T CELL THERAPY AND (S)-3-[4-(4-MORPHOLIN-4-YLMETHYL-BENZYLOXY)-L-OXO-L,3-DIHYDRO-ISOINDOL-2-YL]-PIPERIDINE-2,6-DIONE
#53ORALLY ADMINISTERED SOLID DOSAGE FORM DRUG
#54TARGETED DELIVERY OF NANOCARRIER-CONJUGATED DOXORUBICIN
#55CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY
#56DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY
#57COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
#58COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY
#59Stable liquid formulations of cyclophosphamide and processes to prepare the same
#60COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY WITH NADH DEHYDROGENASE PROTEINS
#61USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)
#62Formulations of creatine and cyclodextrin exhibiting improved bioavailability
#63USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)
#64CANCER THERAPY
#65METHODS AND COMPOSITIONS FOR INFUSION OF TRANSIENTLY ENGRAFTING, SELECTED POPULATIONS OF ALLOGENEIC LYMPHOCYTES TO TREAT CANCER
#66COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA
#67MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE
#68FLUORINE-CONTAINING COMPOUND AND ANTI-CANCER MEDICAL USE THEREOF
#69LOW DOSE IMMUNE CHECKPOINT BLOCKADE IN METASTATIC CANCER
#70TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS
#71VESICLES
#72SYNTHETIC DERIVATIVES OF CHOLIC ACID 7-SULFATE AND USES THEREOF
#73COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS
#74Compositions and methods for treating leber's hereditary optic neuropathy with NADH dehydrogenase proteins
#75INDUCED STEM MEMORY T CELLS AND METHODS OF USE THEREOF
#76Priming of cancer cells with low dose naltrexone
#77LIQUID EMBOLICS
#78Methods of use of cyclopamine analogs
#79COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR
#80Use of inhibitors of Brutons tyrosine kinase (Btk)
#81METHODS OF IDENTIFYING MYC-DRIVEN AND LIPOGENESIS-DEPENDENT NEOPLASMS AND METHODS OF TREATING THE SAME
#82Interactional Biosystem
#83ANTICANCER DRUGS AND METHODS OF MAKING AND USING SAME
#84COMBINATION THERAPY USING ADOPTIVE CELL THERAPY AND CHECKPOINT INHIBITOR
#85ACTIVATED LYMPHOCYTIC CELLS AND METHODS OF USING THE SAME TO TREAT CANCER AND INFECTIOUS CONDITIONS
#86Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
#87Prodrugs Activated by Reduction in the Cytosol
#88PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
#89Materials and methods for suppressing and/or treating bone related diseases and symptoms
#90IBRUTINIB COMBINATION THERAPY
#91TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS
#92Compositions and methods for treating leber's hereditary optic neuropathy
#93Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug
#94METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
#95Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof
#96Cancer immunotherapy using transfusions of allogeneic, tumor-specific CD4+ T cells
#97Use of inhibitors of Bruton's tyrosine kinase (Btk)
#98Treatment of aneurysms
#99Cyclopamine analogs
#100SOLID FOSMETPANTOTENATE FORMULATIONS
#101ARENAVIRUS PARTICLES TO TREAT SOLID TUMORS
#102NANOSCALE CARRIERS FOR THE DELIVERY OR CO-DELIVERY OF CHEMOTHERAPEUTICS, NUCLEIC ACIDS AND PHOTOSENSITIZERS
#103DPEP-1 binding compositions and methods of use
#104Compositions and methods for selective elimination and replacement of hematopoietic stem cells
#105PRODRUGS OF 2-PMPA FOR HEALTHY TISSUE PROTECTION DURING PSMA-TARGETED CANCER IMAGING OR RADIOTHERAPY
#106Methods of use of cyclopamine analogs
#107METHODS FOR THE TREATMENT OF B CELL MALIGNANCIES USING ADOPTIVE CELL THERAPY
#108Use of inhibitors of bruton's tyrosine kinase (BTK)
#109Stable liquid formulations of cyclophosphamide and its impurities
#110COMPOSITIONS AND METHODS FOR FORECASTING RESPONSE TO LUPUS NEPHRITIS (LN)THERAPY
#111Compositions and methods for treatment of cancer using bacteria
#112Methods for non-myeloablative bone marrow reconstitution
#113NOVEL IMMUNOTHERAPEUTIC TREATMENTS FOR TUMOURS
#114Veliparib in Combination With Carboplatin for the Treatment of Triple Negative Breast Cancer
#115Cancer therapy
#116Composition and method for reducing neutropenia
#117Therapeutic antitumor combination of a TLR4 ligand with other treatments
#118Compositions and methods of cellular immunotherapy
#119Compositions and methods for inhibiting tumor-induced immune suppression
#120Induced Stem Memory T-Cells and Methods of Use Thereof
#121TH-302 solid forms and methods related thereto
#122METHODS AND COMPOSITIONS FOR DOSING OF ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR T CELLS
#123TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS
#124Hydrogen sulfide (H2S) releasing donor compound for dermal wound regeneration
#125Combination Therapies Employing GITR Binding Molecules
#126TREATMENT OF CANCERS WITH IMMUNOSTIMULATORY HIV TAT DERIVATIVE POLYPEPTIDES
#127COMBINING ADENOVIRUS AND CHEMOTHERAPEUTIC AGENTS FOR TREATING CANCER
#128Cyclopamine analogs
#129Tumor therapeutic agent
#130Methods of conditioning patients for T cell therapy
#131Methods of use of cyclopamine analogs
#132METHODS AND COMPOSITIONS FOR INFUSION OF TRANSIENTLY ENGRAFTING, SELECTED POPULATIONS OF ALLOGENEIC LYMPHOCYTES TO TREAT CANCER
#133USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
#134Use of inhibitors of bruton's tyrosine kinase (Btk)
#135IL-8 inihibitors for use in the treatment of some urological disorders
#136Treatment of graft versus host disease in transplant patients
#137TREATMENT OF HER2-POSITIVE BREAST CANCER
#138Treatment of diffuse large-cell lymphoma with anti-CD20 antibody
#139Dosing strategies for targeting EPCAM positive bladder cancer
#140THERAPEUTIC COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
#141Use of inhibitors of Bruton's tyrosine kinase (Btk)
#142Use of inhibitors of Bruton's tyrosine kinase (Btk)
#143Treatment or prophylaxis of proliferative conditions
#144Methods of conditioning patients for T cell therapy
#145Methods of use of cyclopamine analogs
#146COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C VIRUS
#147Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
#148Treatment of cancers with immunostimulatory HIV Tat derivative polypeptides
#149DPEP-1 binding compositions and methods of use
#150Nitrogen-containing analogs of salinomycin, synthesis and use against cancer stem cells and malaria
#151FORMULATIONS OF CYCLOPHOSPHAMIDE LIQUID CONCENTRATE
#152METHODS AND COMPOSITIONS FOR IMPROVING OUTCOMES OF LIPOSOMAL CHEMOTHERAPY
#153AN ANTI-CD45RC ANTIBODY FOR USE AS DRUG
#154METHODS OF TREATING A DISEASE OR DISORDER ASSOCIATED WITH BRUTON'S TYROSINE KINASE
#155TH-302 solid forms and methods related thereto
#156Method for detecting GABAA receptor autoantibodies
#157Stable liquid formulations of cyclophosphamide and processes to prepare the same
#158Priming of cancer cells with low dose naltrexone
#159USEFUL PROCESS FOR SCREENING IMMUNE RESPONSE MODIFIER
#160PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
#161Derivatives of oxazaphosphorines and therapeutic uses thereof
#162ANTITUMOR COMBINATIONS CONTAINING ANTIBODIES RECOGNIZING SPECIFICALLY CD38 AND CYCLOPHOSPHAMIDE
#163TREATMENT OF DIFFUSE LARGE-CELL LYMPHOMA WITH ANTI-CD20 ANTIBODY
#164Use of inhibitors of Bruton'S tyrosine kinase (Btk)
#165CLASSIFICATION OF MYC-DRIVEN B-CELL LYMPHOMAS
#166Cyclopamine analogs
#167Methods for treating cancer using apilimod
#168Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
#169VELIPARIB IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
#170THERAPEUTIC COMPOSITIONS AND METHODS INVOLVING CELL-PERMEABLE IRON
#171Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells
#172Methods of conditioning patients for T cell therapy
#173Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers
#174COMPOSITIONS AND METHODS FOR INDUCING DIFFERENTIATION OF STEM CELLS
#175COMBINATION THERAPIES EMPLOYING GITR BINDING MOLECULES
#176Use of inhibitors of bruton's tyrosine kinase (BTK)
#177METHODS FOR PREDICTING AN INDIVIDUAL'S CLINICAL TREATMENT OUTCOME FROM SAMPLING A GROUP OF PATIENT'S BIOLOGICAL PROFILES
#178Method of immunotherapy for treatment of human papillomavirus infection
#179Herbal formulations
#180IBRUTINIB COMBINATION THERAPY
#181VSTM5 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED DISEASES
#182Predictive biomarker for hypoxia-activated prodrug therapy
#183Compositions and methods for treatment of cancer using bacteria
#184Compositions comprising rutin useful for the treatment of tumors resistant to chemotherapy
#185Compositions and methods for treatment of cancer using bacteria
#186METHODS FOR PREDICTING DRUG RESPONSIVENESS IN CANCER PATIENTS
#187VESICLES
#188Use of inhibitors of bruton's tyrosine kinase (Btk)
#189Methods of use of cyclopamine analogs
#190Enzyme conjugate and prodrug cancer therapy
#191MUCINOUS GLYCOPROTEIN (MUC-1) VACCINE
#192Topical transdermal method for delivering nutrients through the skin for expeditied wound healing and skin rejuvenation
#193Cancer therapy
#194COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXITY (ADCC)
#195TREATMENT OF GRAFT VERSUS HOST DISEASE IN TRANSPLANT PATIENTS
#196CHOLESTANOL DERIVATIVE FOR COMBINED USE
#197Method of treating ovarian cancer using a PKC inhibitor
#198Use of fusion protein
#199Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
#200Formulations of cyclophosphamide liquid concentrate
#201FORMULATIONS OF CYCLOPHOSPHAMIDE LIQUID CONCENTRATE
#202Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
#203Lymphoma prognostic methods and kits
#204Veliparib in combination with carboplatin for the treatment of triple negative breast cancer
#205Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
#206Compositions and methods for treating hepatitis C virus
#207Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
#2086-oxopurine phosphoribosyltransferase inhibitors
#209Treatment of cancers with immunostimulatory HIV tat derivative polypeptides
#210Organophosphates for treating afflictions of the skin
#211Anti-tumor adjuvant therapy
#212Compounds for treating proliferative disorders
#213Cyclopamine analogs
#214Vaccine immunotherapy for treating cervical cancer in immune suppressed patients
#215Vaccine immunotherapy for treating lymphoma in immune suppressed patients
#216Induction of differential stress resistance and uses thereof
#217Small molecule inhibitors of Mcl-1 and the uses of thereof
#218PD-1 Antagonists and Methods for Treating Infectious Disease
#219Compositions and methods for treatment of cancer using bacteria
#220Compositions and methods for treatment of cancer
#221Topical Transdermal Method for Delivering Nutrients Through the Skin for Expeditied Wound Healing and Skin Rejuvenation
#222Use of inhibitors of bruton's tyrosine kinase (BTK)
#223Salts of isophosphoramide mustard and analogs thereof
#224Immuno gene therapy for treatment of cancer and hyperproliferative diseases
#225Methods of use of cyclopamine analogs
#226Method of treatment using checkpoint kinase 1 inhibitors
#227Nanocapsulation of essential oils for preventing or curing infectious diseases alone or with an antibiotic
#228High-Energy Compounds for Use in Alzheimer's and Other Neurodegenerative Diseases
#229VACCINE IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS
#230Peptidomimetic inhibitors of PSMA
#231CONCOMITANT DRUG FOR IMPROVING COGNITIVE FUNCTION
#232PHOSPHO-ESTER DERIVATIVES AND USES THEREOF
#233COMBINATION THERAPY INCLUDING ISOPHOSPHORAMIDE MUSTARD, ANALOGS, OR SALTS THEREOF
#234Novel IDO Inhibitors and Methods of Use Thereof
#235METHOD FOR DECREASING SEBUM PRODUCTION
#236Use of armillaridin for treating cancer
#237CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR
#238Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
#239Compositions and methods for treatment of cancer
#240Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
#241Nucleoside phosphoramidates
#242TRIAZOLOPYRIDINE DERIVATIVES
#243Nitrogenated derivatives of pancratistatin
#244METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS
#245Methods of use of cyclopamine analogs
#246CHOLESTANOL DERIVATIVE FOR COMBINED USE
#247TOPICAL TRANSDERMAL METHOD FOR DELIVERING NUTRIENTS THROUGH THE SKIN FOR EXPEDITED WOUND HEALING
#248Induction of differential stress resistance and uses thereof
#249TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS
#250COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC)
#251CHEMICAL STRUCTURE COMPRISING PHOSPHATES WITH POLYOL SUBSTRUCTURES FOR HAIR AND SKIN COSMETICS USAGE
#252EZATIOSTAT FOR TREATING MULTIPLE MYELOMA
#253Method of immunotherapy for treament of human papillomavirus infection
#254Compositions and methods for the treatment of musculoskeletal related diseases and disorders using metal ion-citrate analog complexes
#255TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS
#256TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS
#257Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
#258HYDROGELS USED TO DELIVER MEDICAMENTS TO THE EYE FOR THE TREATMENT OF POSTERIOR SEGMENT DISEASES
#259Use of inhibitors of bruton's tyrosine kinase (Btk)
#260Cyclophosphamide in combination with anti-idiotypic vaccines
#261Methods of Prognosis for Non-Hodgkin Lymphoma
#262USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS IN COMBINATION WITH MONOCLONAL ANTIBODIES FOR TREATING IMMUNE DISORDERS
#263Cyclophosphamide in combination with immune therapeutics
#264THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
#265COMBINED USE OF CREATINE PHOSPHATE AND CREATINE PHOSPHOKINASE FOR TREATMENT OF ARTERIOSCLEROSIS
#266USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
#267Methods of use of cyclopamine analogs
#268Formulations of canfosfamide and their preparation
#269CHOLESTANOL DERIVATIVE FOR COMBINED USE
#270CHOLESTANOL DERIVATIVE FOR COMBINED USE
#271ANTITUMOR COMBINATIONS CONTAINING ANTIBODIES RECOGNIZING SPECIFICALLY CD38 AND CYCLOPHOSPHAMIDE
#272Herbal formulations
#273METHODS OF USE FOR CYCLOPAMINE ANALOGS
#274Formulations of canfosfamide and their preparation
#275TARGETED COSTIMULATORY POLYPEPTIDES AND METHODS OF USE TO TREAT CANCER
#276Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
#277Quinazolinone Compounds and Methods of Use Thereof
#278Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
#279PD-1 ANTAGONISTS AND METHODS OF USE THEREOF
#280COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC)
#281PD-1 ANTAGONISTS AND METHODS FOR TREATING INFECTIOUS DISEASE
#282Nitrogenated derivatives of pancratistatin
#283TREATMENT OF CYSTIC DISEASE WITH LYSOPHOSPHATIDIC ACID ANTAGONISTS
#284NOVEL LIPOPHILIC COMPOSITIONS AND USES THEREOF
#285COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC)
#286Treatment or prophylaxis of proliferative conditions
#287USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM
#288Nucleoside phosphoramidates
#289Methods of use of cyclopamine analogs
#290Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
#291Method of treatment using checkpoint kinase 1 inhibitors
#292TREATMENT REGIME FOR PROLIFERATIVE DISORDERS
#293Compositions and methods for treatment of cancer
#294Method and Composition for Treating Alzheimer's Disease and Dementias of Vascular Origin
#295Method and Composition for Treating Alzheimer's Disease and Dementias of Vascular Origin
#296DIAMINOQUINAZOLINE INHIBITORS OF DIHYDROFOLATE REDUCTASE
#297PODOPHYLLOTOXIN INHIBITORS OF TOPOISOMERASE II
#298Method for decreasing sebum production
#299Compounds for treating proliferative disorders
#300IDO inhibitors and methods of use thereof